Table 5:

Recent retrospective studies on the oncologic outcomes of stereotactic body radiotherapy to treat localized renal cell carcinoma.

Study	Year	Experimental design	Intervention	Patient population	Number of patients/studies	Outcomes	Follow-up	Conclusion
Correa et al.	2019	Systematic review, meta-analysis	SBRT	All stages, RCC	Studies = 26 Patients = 372	LC	Median = 28 months	LC = 97.2%
Siva et al.	2020	Retrospective Multi-institution	SBRT	≥ T1b, nonmetastatic RCC	Patients = 95	CSS OS PFS	Median = 2.7 years	4-yr CSS = 91.4% 4-yr OS = 69.2% 4-yr PFS = 64.9%
Yamamoto et al.	2021	Retrospective Single institution	SBRT	Clinical or recurrent T1 RCC	Patients = 29	LC LR CPF DSS OS	Median = 57 months	5-yr LC = 94% 5-yr LRC = 88% 5-yr PFS = 50% 5-yr DSS = 96% 5-yr OS = 68%

CSS, cancer-specific survival; DSS, disease-specific survival; LC, local control; LRC, loco-regional control; OS, overall survival; PFS, progression-free survival; RCC, renal cell carcinoma; SBRT, stereotactive body radiotherapy.